Skip to main content
Premium Trial:

Request an Annual Quote

Indianapolis Biomarker Cancer Dx Firm Reels in $6.3M in Series A Funding

NEW YORK (GenomeWeb News) – Indianapolis-based company CS-Keys has gained nearly $6.3 million in Series A financing from previous and new investors, the company said today.
 
The cash infusion will fund the company’s initial product offering, the caPCNA Key Stain, a stain used to help pathologists detect the occurrence and re-occurrence of several types of cancer, including colorectal, breast, prostate, and ovarian cancers.
 
The financing round included investments from Triathlon Medical Ventures, which seeded the company, Clarian Health Ventures, Prolog Ventures, Ceres Venture Fund, and Spring Mill Venture Partners.
 
The company also is developing other biomarker-based diagnostics, including the caPCNA Elisa and caPCNA Cytology products.
 
 

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more